Table 1.
Clinical and transplant characteristics.
| Training cohort | Validation cohort | Total | |
|---|---|---|---|
| N° | 23 | 12 | 35 |
| Median age | 55 years (r: 18-69) | 50 years (r: 28-69) | 55 years (r: 18-69) |
| Female (F)/Male(M) | 8/15 | 6/6 | 14/21 |
| Donor/Recipient sex mismatch (F/M) | n=2 (8.7%) | n=1 (8.3%) | n=3 (8.6%) |
| Diagnosis | |||
| AML ALL MDS LYMHOMAS OTHERS |
n=9 (39.1%) n=4 (17.4%) n=4 (17.4%) n=2 (8.7%) n=4 (17.4%) |
n=5 (41.7%) n=2 (16.7%) n=1 (8.3%) n=2 (16.7%) n=2 (16.7%) |
n=14 (40.0%) n=6 (17.1%) n=5 (14.2%) n=4 (11.4%) n=6 (17.1%) |
| Phase at transplant | |||
| Early Advanced |
n=13 (56.5%) n=10 (43.5%) |
n=4 (33.4%) n=8 (66.6%) |
n=17 (48.6%) n=18 (51.4%) |
| HLA matching | |||
| HLA 10/10 HLA 9/10 HLA 8/10 HLA 8/8 HLA 7/8 |
n=14 (60.8%) n=8 (34.8%) n=1 (4.4%) n=16 (69.6%) n=7 (30.4%) |
n=7 (58.3%) n=3 (25.0%) n=2 (16.7%) n=7 (58.3%) n=5 (41.7%) |
n=21 (60.0%) n=11 (31.4%) n=3 (8.6%) n=23 (65.7%) n=12 (34.3%) |
| Donor type | |||
| Matched Related Matched Unrelated* Mismatched Unelated |
n=1 (4.4%) n=13(56.5%) n=9 (39.1%) |
n=1 (8.3%) n=6 (50.0%) n=5 (41.7%) |
n=2 (5.7%) n=19 (54.3%) n=14 (40.0%) |
| Stem Cell Source | |||
| PBSC | n=23 (100%) | n=12 (100%) | n=35 (100%) |
| Conditioning intensity: | |||
| myeloablative reduced intensity |
n=12 (52.2%) n=11 (47.8%) |
n=7 (58.3%) n=5 (41.7%) |
n=19 (54.3) n=16 (45.7%) |
| GVHD Prophylaxis | |||
| CSA-MTX-rATLG CSA-MMF-rATLG |
n=21 (91.3%) n=2 (8.7%) |
n=12 (100%) n=0 |
n=33 (94.3%) n=2 (5.7%) |
| Acute GVHD | n=11 (47.8%) | n=6 (50.0%) | n=17 (48.7%) |
| Grade 1 Grade 2 Grade 3 Grade 4 Median time of onset (range) |
n=3 (13.0%) n=3 (13.0%) n=3 (13.0%) n=2 (8.8%) 36 days (r: 11-157) |
n=2 (16.7%) n=3 (25.0%) n=1 (8.3%) n=0 34 days (r: 17-129) |
n=5 (14.3%) n=6 (17.1%) n=4 (11.4%) n=2 (5.7%) 36 (r: 11-157) |
| Chronic GVHD | n=4 (17.4%) | n=2 (16.7%) | n=6 (17.1%) |
| Mild Moderate Severe Median time of onset (range) |
n=2 (8.7%) n=1 (4.9%) n=1 (4.9%) 119 days (r: 53-328) |
n=0 (0.0%) n=0 (0.0%) n=2 (16.7%) 183 days (r: 139-227) |
n=2 (5.7%) n=1 (2.8%) n=3 (8.6%) 158 (r: 56-328) |
| Acute/Chronic GVHD combination | |||
| Acute or Chronic GvHD Acute and Chronic GvHD Only Acute GvHD Only Chronic GvHD |
n=12 n=3 (25.0%) n=8 (66.7%) n=1 (8.3%) |
n=6 (50.0%) n=2 (16.7%) n=4 (33.3%) n=0 |
n=18 (51.4%) n=5 (14.3%) n=12 (34.3%) n=1 (2.8%) |
| Median Follow Up time(range) | 463 days (r: 48-645) | 272 days (r: 200-399) | 421 (r: 48-645) |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; HLA, human leukocyte antigen; GVHD, graft versus host disease; CSA, Ciclosporin; MTX, methotrexate; rATLG, rabbit anti-T –lymphoglobulin.